Date:11/27/2007

Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements include, without limitation, the FDA's acceptance of our proposed study amendments, and whether our two clinical trials will have the potential to form the basis of a Phase III trial submission to the FDA. While management has based any forward- looking statements contained herein on its current expectations, the information on which such expectations were based may change. These forward- looking statements rely on a number of assumptions concerning future events and are subject to a number of risks, uncertainties, and other factors, many of which are outside of our control, that could cause actual results to materially differ from such statements. Such risks, uncertainties, and other factors include, but are not necessarily limited to, those set forth under Item 1A "Risk Factors" in the Company's Annual Report on Form 10-K for the year ended December 31, 2006, as updated in "Item 1A. Risk Factors" in the Company's Quarterly Reports on Form 10-Q. We operate in a highly competitive and rapidly changing environment, thus new or unforeseen risks may arise. Accordingly, investors should not place any reliance on forward-looking statements as a prediction of actual results. We disclaim any intention to, and undertake no obligation to, update or revise any forward-looking statements. Readers are also urged to carefully review and consider the other various disclosures in the Company's Annual Report on Form 10-K for the year ended December 31, 2006, as well as other public filings with the SEC since such date.

'/>"/>

SOURCE Isolagen, Inc. Copyright©2007 PR Newswire. All rights reserved

0 GOOD

Page: 1 2 3
Related medicine news :

1. Isolagen, Inc. Postpones Annual Meeting
2. Isolagen Initiates Phase III Clinical Program to Investigate Isolagen Therapy(TM) for the Treatment of Acne Scars
3. CNS Response, Inc. Modifies rEEG(SM) Trial Protocol for Treatment-Resistant Depression Study
4. Middle School Marks Most Critical Time to Start Ongoing Conversations About Drug and Alcohol Use With Kids
5. Dr. Dan L. Fortenbacher, O.D., FCOVD, Becomes 29th President of College of Optometrists in Vision Development (COVD); Unveils 7-Part Development Plan for Ongoing Growth
6. Radiologists encouraged to look beyond cancer for clinically unseen diseases
7. Clinical depression linked to abnormal emotional brain circuits
8. Preclinical study suggests organ-transplant drug may aid in lupus fight
9. Provectus Pharmaceuticals, Inc. Begins Phase 2 Clinical Trial for Metastatic Melanoma
10. Good Clinical Practice Journal Awards: Winners Announced
11. Microsoft Helps Developers of Clinical User Interfaces Improve Efficiency, Patient Safety With Free Toolkit